Royalty Pharma Acquires Royalty Interest In Imdelltra From BeOne

Royalty Pharma (RPRX) has acquired a royalty interest in Amgen's bispecific T-cell engager, Imdelltra, from BeOne Medicines for $885 million upfront, with an option for an additional $65 million. Imdelltra received FDA accelerated approval in May 2024 for extensive-stage small cell lung cancer and is undergoing Phase 3 studies for front-line SCLC, positioning this acquisition to capitalize on the drug's significant market potential. BeOne retains China commercial rights.

Analysis

Royalty Pharma plc (RPRX) has executed a significant capital deployment, acquiring a royalty interest in Amgen's Imdelltra for an upfront payment of $885 million. This transaction secures for RPRX a stake in a promising oncology asset that received accelerated FDA approval in May 2024 for treating extensive-stage small cell lung cancer (SCLC) in patients who have progressed after platinum-based chemotherapy. The strategic rationale for the acquisition appears to be rooted not just in the current indication, but in the substantial upside potential from ongoing Phase 3 studies evaluating Imdelltra as a front-line SCLC treatment. A positive outcome in this front-line setting would dramatically increase the drug's target patient population and revenue potential. The deal structure, which includes a potential further $65 million payment, also has a key geographical limitation: BeOne Medicines retains commercial rights for China, carving out a major market from RPRX's royalty stream. The strongly positive sentiment associated with RPRX reflects market confidence in this acquisition of a de-risked, late-stage asset with a clear path to market expansion.

Key Decisions for Investors

• Investors in Royalty Pharma should view this acquisition as a positive strategic move that adds a de-risked oncology asset with significant upside; the primary catalyst to monitor will be the data readouts from Amgen's Phase 3 trials for Imdelltra in front-line SCLC.
• When modeling future revenue for RPRX from this asset, it is critical to exclude potential sales from China, as BeOne Medicines has retained commercial rights for that territory, thereby capping the total addressable market for this royalty interest.
• For investors holding Amgen, this transaction provides third-party validation of Imdelltra's commercial potential and may increase confidence in the value of its late-stage oncology pipeline ahead of key clinical trial results.